Dronabinol low-dose - RespireRx Pharmaceuticals

Drug Profile

Dronabinol low-dose - RespireRx Pharmaceuticals

Alternative Names: PP-001 - Pier

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Pier Pharmaceuticals
  • Developer Northwestern University; RespireRx Pharmaceuticals; University of Chicago; University of Illinois
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sleep apnoea syndrome

Most Recent Events

  • 06 Jan 2017 RespireRx Pharmaceuticals plans a phase III trial for Obstructive sleep apnea in USA
  • 23 Dec 2016 Efficacy data from the phase IIb PACE trial in Sleep apnoea syndrome released by RespireRx Pharmaceuticals
  • 01 Aug 2016 University of Illinois completes a phase-IIb trial for Sleep apnoea syndrome in USA (NCT01755091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top